Vocal aging and adductor spasmodic dysphonia: Response to botulinum toxin injection

Clinical Interventions in Aging

Volumn 3, Issue 1, 2008, Pages 131-151

  Cannito, Michael P ^a   Kahane, Joel C ^a   Chorna, Lesya ^a  

^a UNIVERSITY OF MEMPHIS   (United States)

Author keywords

Adductor spasmodic dysphonia; Botulinum toxin; Speech fluency; Vocal aging; Voice quality

Indexed keywords

BOTULINUM TOXIN A;

ADDUCTOR SPASMODIC DYSPHONIA; AGING; DRUG EFFICACY; DRUG MECHANISM; DRUG MEGADOSE; DYSPHONIA; GLOTTIS; HUMAN; LAMINA PROPRIA; LARYNGEAL NERVE; LARYNX MUCOSA; LARYNX MUSCLE; LOADING DRUG DOSE; MUSCLE INNERVATION; NEUROMUSCULAR SYNAPSE; NONHUMAN; RETROSPECTIVE STUDY; REVIEW; VOCAL CORD; VOCAL CORD DISORDER; VOICE;

BOTULINUM TOXIN TYPE A; HUMANS; INJECTIONS; LARYNGEAL MUSCLES; LARYNGEAL NERVES; MUCOUS MEMBRANE; NEUROMUSCULAR AGENTS; RETROSPECTIVE STUDIES; VOCAL CORDS; VOICE; VOICE DISORDERS;

EID: 42449118425     PISSN: 11769092     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (98)

1. Ali SO, Thomassen M, Schulz GM, et al. 2006. Alterations in CNS activity induced by botulinum toxin treatment in spasmodic dysphonia: an H215O PET study. J Speech Lang Hear Res, 49:1127-46.
2. Amerman JD, Parnell MM. 1990. Auditory impressions of the speech of normal elderly adults. Br J Disord Commun, 25:35-43.
3. Aronson AE. 1990. Clinical voice disorders. 3 edition edn, New York: Thieme Medical Publishers.
4. Aronson AE, McCaffrey TV, Litchey WJ, et al. 1993. Botolinum toxin injection for adductor spasmodic dysphonia: Patient self-rating of voice and phonatory effort after three successive injections. Laryngoscope, 103:683-91.
5. Assessment: the clinical usefulness of botulinum toxin-A in treating neurologic disorders. Report of Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. 1990.
6. Bach AC, Lederer FL, Dinolt R. 1942. Senile changes in the laryngeal musculature. AMA Archives of Otolaryngology, 47-56.
7. Benjamin BJ. 1982. Phonological performance in gerontological speech. J Psycholinguist Res, 11:159-67.
8. Blitzer A, Brin MF. 1992. The dystonic larynx. Journal of Voice, 6:294-7.
9. Blitzer A, Brin MF. 1992. Treatment of spasmodic dysphonia (laryngeal dystonia) with local injections of botulinum toxin. Journal of Voice, 6:365-9.
10. Blitzer A, Brin MF, Stewart CF. 1998. Botülinum toxin management of spasmodic dysphonia (laryngeal dystonia): a 12-year experience in more than 900 patients. Laryngoscope, 108:1435-41.
11. Boutsen F, Cannito MP, Taylor M, et al. 2002. Botox treatment in adductor spasmodic dysphonia: a meta-analysis. J Speech Lang Hear Res, 45:469-81.
12. Brodnitz FS. 1976. Spastic dysphonia. Ann Otol Rhinol Laryngol, 85:210-4.
13. Cannito MP, Woodson GE. 2000. The Spasmodic Dysphonias. In: Kent RD, Ball MJ eds. Voice quality measurement. San Diego: Singular Publishing Group. p. 411-30.
14. Cannito MP, Woodson GE, Murry T, et al. 2004. Perceptual analyses of spasmodic dysphonia before and after treatment. Arch Otolaryngol Head Neck Surg, 130:1393-9.
15. Camevalle-Ricci R. 1937. Osservazioni isopatologiche sulla laringe nella senescenza. Archivo Italiano di Otologi, Rhinologia e Laringologia, 49.
16. Connor NP, Suzuki T, Lee K, et al. 2002. Neuromuscular junction changes in aged rat thyroarytenoid muscle. Ann Otol Rhinol Laryngol, 111:579-86.
17. Davidson BJ, Ludlow CL. 1996. Long-term effects of botulinum toxin injections in spasmodic dysphonia. Ann Otol Rhinol Laryngol, 105:33-42.
18. de Paiva A, Meunier FA, Molgo J, et al. 1999. Functional repair of motor endplates after botalinum neurotoxin type A poisoning: biphasic switch of synaptic activity between nerve sprouts and their parent terminals. Proc Natl Acad Sci USA, 96:3200-5.
19. DelGaudio JM, Sciote JJ. 1997. Changes in myosin expression in denervated laryngeal muscle. Ann Otol Rhinol Laryngol, 106:1076-81.
20. Devous MD Sr, Pool KD, Finitzo T, et al. 1990. Evidence for cortical dysfunction in spasmodic dysphonia: regional cerebral blood flow and quantitative electrophysiology. Brain Lang, 39:331-44.
21. Duchen LW. 1970. Changes in motor innervation and cholinesterase localization induced by botulinum toxin in skeletal muscle of the mouse: differences between fast and slow muscles. J Neurol Neurosurg Psychiatry, 33:40-54.
22. Duchen LW. 1972. Motor nerve growth induced by botulinum toxin as a regenerative phenomenon. Proc R Soc Med, 65:196-7.
23. Duchin SW, Mysak ED. 1987. Disfluency and rate characteristics of young adult, middle-aged, and older males. J Commun Disord, 20:245-57.
24. Duxson MJ, Vrbová G. 1985. Inhibition of acetylcholinesterase accelerates axon terminal withdrawal at the developing rat neuromuscular junction. J Neurocytol, 14:337-63.
25. Endres W, Bambach W, Flosser G. 1971. Voice spectrograms as a function of age, voice disguise, and voice imitation. J Acoust Soc Am, 49:1842-8.
26. Ferreri G. 1959. Senescence of the Larynx. Italian General Review of Otorhinolaryngology, 1:640-706.
27. Finitzo T, Freeman FJ. 1989. Spasmodic dysphonia, whether and where: results of seven years of research. Journal of Speech and Hearing Research, 32:541-55.
28. Fisher KV, Scherer RC, Swank PR, et al. 1999. Electroglottographic tracking of phonatory response to botox. Journal of Voice, 13:203-18.
29. Ford CN, Bless DM, Patel NY. 1992. Botulimun toxin treatment of spasmodic dysphonia: Techniques, indications, efficacy. Journal of Voice, 6:370-6.
30. Ford CN, Bless DM, Ptel NY. 1992. Botulimun toxin treatment of spasmodic dysphonia: Techniques, indications, efficacy. Journal of Voice, 6:370-6.
31. Forrest K, Weismer G, Turner GS. 1989. Kinematic, acoustic, and perceptual analyses of connected speech produced by parkinsonian and normal geriatric adults. J Acoust Soc Am, 85:2608-22.
32. Gambino DR, Malingren LT, Gacek RR. 1990. Age-related changes in the neuromuscular junctions in the human posterior cricoarytenoid muscles: a quantitative study. Laryngoscope, 100:262-8.
33. Gracco C, Kahane JC. 1989. Age related changes in the vestibular folds of the human larynx. A histomorphometric study. Journal of Voice, 3:204-12.
34. Gray SD, Titze IR, Chan R, et al. 1999. Vocal fold proteoglycans and their influence on biomechanics. Laryngoscope, 109:845-54.
35. Hambleton D. 1993. Therapeutic application of botulinum toxin. J Med Microbiol, 39:243-5.
36. Hartman DE. 1979. The perceptual identity and characteristics of aging in normal male adult speakers. J Commun Disord, 12:53-61.
37. Haslinger B, Erhard P, Dresel C, et al. 2005. "Silent event-related" fMRI reveals reduced sensorimotor activation in laryngeal dystonia. Neurology, 65:1562-9.
38. Hirano M, Sato K, Nakashima T. 2000. Fibroblasts in geriatric vocal fold mucosa. Acta Otolaryngol, 120:336-40.
39. Hoit JD, Watson PJ, Hixon KE, et al. 1994. Age and velopharyngeal function during speech production. J Speech Hear Res, 37:295-302.
40. Hommerich KW. 1972. Der Altemde Larynx: Morphologische Aspekte. Hals Nasen Ohrenaerzte, 20:115-20.
41. Horjo I, Isshiki N. 1980. Laryngoscopic and voice characteristics of aged persons. Arch Otolaryngol, 106:149-50.
42. Kahane JC. 1981. Anatomic and physiologic changes in the aging peripheral speech mechanism. In: Beasley DS, Davis GA eds. Aging: communication process and disorders. New York: Grune and Stratton. p. 21-45.
43. Kahane JC. 1987. Connective tissue changes in the larynx and their effects on voice. Journal of Voice, 1:27-30.
44. Kahane JC. 1988. Age related changes in the human cricoarytenoid joint. In: O Fujimura ed. Vocal physiology: Voice production, mechanisms, and functions. New York: Raven Press. pp. 145-57.
45. Kahane JC. 1990. Age-related changes in the peripheral speech mechanism: Structural and physiological changes, paper presented to Research Symposium on Communication Sciences and Disorders and Aging. Rockville, MD.
46. Kahane JC. 1996. Life span changes in the larynx: an anatomical perspective. In: WSJR Brown, BP Vinson and MA Crary eds. Organic Voice Disorders: assessment and treatment. San Diego: Singular. pp. 89-111.
47. Kahn AR, Kahane JC. 1986. India ink pinprick assessment of age-related changes in the cricoarytenoid joint (CAJ) articular surfaces. J Speech Hear Res, 29:53 6-43.
48. Kawabuchi M, Zhou CJ, Wang S, et al. 2001. The spatiotemporal relationship among Schwann cells, axons and postsynaptic acetylcholine receptor regions during muscle reinnervation in aged rats. Anat Rec, 264:183-202.
49. Kersing W, Jennekens FG. 2004. Age-related changes in human thyroarytenoid muscles: a histological and histochemical study. Eur Arch Otorhinolaryngol, 261:386-92.
50. Knutsson E, Martensson A, Martensson B. 1969. The normal electromyogram in human vocal muscles. Acta Otolaryngol, 68:526-36.
51. Langveldt TPN, van Rossum MMA, Houtman EH, et al. 2001. Evaluation of voice quality in adductor spasmodic dysphonia before and after botulinum toxin treatment. Annals of Otol Rhynol Laryngol, 110:627-34.
52. Linville SE. 1996. The sound of senescence. J Voice, 10:190-200.
53. Liss JM, Weismer G, Rosenbek JC. 1990. Selected acoustic characteristics of speech production in very old males. J Gerontol, 45:P35-45.
54. Liu TC, Irish JC, Adams SG, et al. 1996. Prospective study of patient subjective responses to botulinum toxin injection for spasmodic dysphonia. Journal of Otolaryngology, 25:66-74.
55. Ludlow CL. 1995. Management of spasmodic dysphonias. In: Rubin JC, Sataloff RT, Korovin GS, et al. eds. Diagnosis and treatment of voice disorders. New York: Igaku-Shoin Medical Publishing. p. 436-54.
56. Lundy DS, Lu FL, Casiano RR, et al. 1998. The effect of patient factors on response outcomes to Botox treatment of spasmodic dysphonia. Journal of Voice, 12:460-6.
57. Madruga de Melo EC, Lemos M, Aragao Ximenes Filho J, et al. 2003. Distribution of collagen in the lamina propria of the human vocal fold. Laryngoscope, 113:2187-91.
58. Malmgren LT, Fisher PJ, Bookman LM, et al. 1999. Age-related changes in muscle fiber types in the human thyroarytenoid muscle: an immunohistochemical and stereological study using confocal laser scanning microscopy. Otolaryngol Head Neck Surg, 121:441-51.
59. Malmgren LT, Gacek RR. 1981. Histochemical characteristics of muscle fiber types in the posterior cricoarytenoid muscle. Annals of Otology, Rhinology and Laryngology, 90:423-9.
60. Malmgren LT, Ringwood M. 1988. Aging of recurrent laryngeal nerve: an ultrastructural morphometric study. In: Fujimura O ed. Vocal physiology: voice production, mechanisms, and functions. New York: Raven Press.
61. Mardini IA, McCarter RJ, Neal GD, et al. 1987. Contractile properties of laryngeal muscles in young and old baboons. Am J Otolaryngol, 8:85-90.
62. Mehta RP, Goldman SN, Orloff LA. 2001. Long-term therapy for spasmodic dysphonia: acoustic and aerodynamic outcomes. Archives of Otolaryngology-Head and Neck Surgery, 127.
63. Miller RH, Woodson GE, Jankovic J. 1987. Botulinum toxin injection of the vocal fold for spasmodic dysphonia: a preliminary report. Archives of Otolaryngology-Head and Neck Surgery, 113:603-5.
64. Morris R, Brown W. 1987. Age-related voice measures among adult women. Journal of Voice, 1:38-43.
65. Morris R, Brown W. 1994. Age-related differences in speech intensity among adult females. Folia Phoniatrica, 46:64-9.
66. Mortelliti AJ, Malmgren LT, Gacek RR. 1990. Ultrastructural changes with age in the human superior laryngeal nerve. Arch Otolaryngol Head Neck Surg, 116:1062-9.
67. Nagai H, Ota F, Connor NP. 2005. Effect of deficits in laryngeal sensation on laryngeal muscle biochemistry. Ann Otol Rhinol Laryngol, 114:352-60.
68. Noell G. 1962. [On the problem of age-related changes of the laryngeal mucosa.]. Arch Ohren Nasen Kehlkopfheilkd, 179:361-5.
69. Orlikoff RF. 1990. The atherosclerotic voice. Ear Nose Throat J, 69:833-7.
70. Périé S, St Guily JL, Callard P, et al. 1997. Innervation of adult human laryngeal muscle fibers. Journal of the Neurological Sciences, 149:81-6.
71. Pestronk A, Drachman DB. 1978. The effect of aging on nerve sprouting. Trans Am Neurol Assoc, 103:14-8.
72. Prakash YS, Sieck GC. 1998. Age-related remodeling of neuromuscular junctions on type-identified diaphragm fibers. Muscle Nerve, 21:887-95.
73. Ramig LA, Ringel RL. 1983. Effects of physiological aging on selected acoustic characteristics of voice. J Speech Hear Res, 26:22-30.
74. Rhew K, Fiedler DA, Ludlow CL, et al. 1994. Technique for injection of Botulinum toxin through the flexible nasolaryngoscope'. Otolaryngology-Head and Neck Surgery, 787-94.
75. Rodeno MT, Sanchez-Fernandez JM, Rivera-Pomar JM. 1993. Histochemical and morphometrical ageing changes in human vocal cord muscles. Acta Otolaryngol, 113:445-9.
76. Salvatore AP, Cannito MP, Biswas A, et al. 2007. Longitudinal Study of Temporal Speech Alterations in an Individual with Adductor Spasmodic Dysphonia Treated with Botulinum Toxin. Journal of Medical Speech-Language Pathology, 15:67-82.
77. Sapienza CM, Cannito MP, Murry T, et al. 2002. Acoustic variations in reading produced by speakers with spasmodic dysphonia pre-botox injection and within early stages of post-botox injection. Journal of Speech and Hearing Research, 45:930-43.
78. Sato K, Hirano M. 1997. Age-related changes of elastic fibers in the superficial layer of the lamina propria of vocal folds. Ann Otol Rhinol Laryngol, 106:44-8.
79. Sato K, Hirano M. 1998. Age-related changes in the human laryngeal glands. Ann Otol Rhinol Laryngol, 107:525-9.
80. Sato K, Hirano M, Nakashima T. 2002. Age-related changes of collagenous fibers in the human vocal fold mucosa. Ann Otol Rhinol Laryngol, 111:15-20.
81. Sato K, Hirano M, Nakashima T. 2004. Age-related changes in vitamin A-storing stellate cells of human vocal folds. Ann Otol Rhinol Laryngol, 113:108-12.
82. Sato T, Tauchi H. 1982. Age changes in human vocal muscle. Mech Ageing Dev, 18:67-74.
83. Schantz EJ, Johnson EA. 1992. Properties and use of botulinum toxin and other microbial neurotoxins in medicine. Microbiol Rev, 56:80-99.
84. Scukanec GP, Petrosino L, Colcord RD. 1996. Age-related differences in acoustical aspects of contrastive stress in women. Folia Phoniatr Logop, 48:231-9.
85. Shaari CM, George E, Wu BL, et al. 1991. Quantifying the spread of botulinum toxin through muscle fascia. Laryngoscope, 101:960-4.
86. Simpson LL. 1992. Clinically relevant aspects of the mechanism of action of botulinum neurotoxin. Journal of Voice, 6:358-64.
87. Suzuki T, Connor NP, Lee K, et al. 2002. Age-related alterations in myosin heavy chain isoforms in rat intrinsic laryngeal muscles. Ann Otol Rhinol Laryngol, 111:962-7.
88. Suzuki T, Connor NP, Lee K, et al. 2002. Laryngeal-respiratory kinematics are impaired in aged rats. Ann Otol Rhinol Laryngol, 111:684-9.
89. Takeda N, Thomas GR, Ludlow CL. 2000. Aging effects on motor units in the human thyroarytenoid muscle. Laryngoscope, 110:1018-25.
90. Tanaka S, Hirano M, Chijiwa K. 1994. Some aspects of vocal fold bowing. Ann Otol Rhinol Laryngol, 103:357-62.
91. Thibeault SL, Li W, Gray SD, et al. 2002. Instability of extracellular matrix gene expression in primary cell culture of fibroblasts from human vocal fold lamina propria and tracheal scar. Ann Otol Rhinol Laryngol, 111:8-14.
92. Truong DD, Rontal M, Rolnick M, et al. 1991. Double-blind controlled study of Botulinum toxin in adductor spasmodic dysphonia. Laryngoscope, 101:630-4.
93. Whurr R, Lorch M, Fontana H, et al. 1993. The use of botulinum toxin in the treatment of adductor spasmodic dysphonia. J Neurol Neurosurg Psychiatry, 56:526-30.
94. Wingate JM, Ruddy BH, Lundy DS, et al. 2005. Voice handicap index results for older patients with adductor spasmodic dysphonia. J Voice, 19:124-31.
95. Woo P, Casper J, Colton R, et al. 1992. Dysphonia in the aging: physiology versus disease. Laryngoscope, 102:139-44.
96. Woodson GE. 1994. Determining the optimal dose for botulinum toxin in spasmodic dysphonia, paper presented to The Third International Symposium on Phonosurgery. Kyoto, Japan.
97. Xue SA, Hao GJ. 2003. Changes in the human vocal tract due to aging and the acoustic correlates of speech production: a pilot study. J Speech Lang Hear Res, 46:689-701.
98. Zuber M, Sebald M, Bathien N, et al. 1993. Botulinum antibodies in dystonic patients treated with type A botulinum toxin: frequency and significance. Neurology, 43:1715-8.